Life science company Bio-Rad Laboratories has extended its range of recombinant monoclonal anti-idiotypic antibodies. The company has also launched an anti-Fc mutation antibody range targeting drugs containing YTE mutations.
“The launch of our first anti-Fc mutation range alongside a new range of anti-biotherapeutic antibodies, including our first against a drug acting as a GLP-1 receptor agonist, marks a significant step beyond classical anti-IDs, underscoring how our technology is adaptable to any new drug format and our commitment to drive innovation across antibody drug discovery,” said Bio-Rad Laboratories, life science group marketing director Hilary Mavor.
Th antibodies are specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa), nirsevimab (Beyfortus), and tremelimumab (Imjudo). Bio-Rad also released a recombinant monoclonal anti-biotherapeutic antibody specific to dulaglutide (Trulicity).
The range is suitable for use in preclinical and clinical pharmacokinetic and anti-drug antibody assays, supporting therapeutic drug monitoring for biologic and biosimilar products.
The launch of the anti-Fc mutation antibody range enables the selective detection of YTE-modified therapeutics via the recognition of YTE triple substitutions (M252Y, S254T, and T256E) in the Fc region of human IgG1 antibodies – a modification shown to extend antibody half-life compared to wild-type IgG.
The ready-made antibodies are suitable for the development pf PK bridging ELISAS to measure free drug concentration in serum.
Last year, Bio-Rad expanded its range of StarBright Dyes to enhance panel design capabilities for spectral flow cytometry.
